scholarly journals Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.

2000 ◽  
Vol 47 (1) ◽  
pp. 191-199 ◽  
Author(s):  
J Błasiak ◽  
B Smolarz
Keyword(s):  
Breast Cancer ◽  
Plasminogen Activator ◽  
Pcr Amplification ◽  
Plasminogen Activator Inhibitor ◽  
Cancer Tissue ◽  
Plasminogen Activator Inhibitor 1 ◽  
Node Negative ◽  
Node Positive ◽  
Activator Inhibitor ◽  
Pai 1

The antigen content of plasminogen activator inhibitor-1 (PAI-1) in primary breast cancer tissue extracts may be of strong prognostic value: high levels of PAI-1 in tumors predict poor prognosis for patients. The gene encoding PAI-1 is highly polymorphic and an insertion (5G)/deletion (4G) polymorphism in the PAI-1 gene promoter (the 4G/5G polymorphism), may have functional significance in PAI-1 expression. In the present work the distribution of genotypes and frequency of alleles of the 4G/5G polymorphism in subjects with breast cancer were investigated. Tumor tissues were obtained from 100 postmenopausal women with node-negative and node-positive ductal breast carcinoma with uniform tumor size. Blood samples from age matched healthy women served as control. The 4G/5G polymorphism was determined by PCR amplification using the allele specific primers. The distribution of the genotypes of the 4G/5G polymorphism in both control and patients did not differ significantly (P > 0.05) from those predicted by the Hardy-Weinberg distribution. There were no differences in the genotype distributions and allele frequencies between node-positive and node-negative patients. The 4G/5G polymorphism may not be linked with elevated level of PAI-1 observed in breast cancer and therefore may not be associated with appearance and/or progression of breast cancer.

scholarly journals Plasminogen activator inhibitor 1 (PAI-1) 1334G/A genetic polymorphism in colorectal cancer.

2003 ◽  
Vol 50 (2) ◽  
pp. 489-495 ◽  
Author(s):  
Beata Smolarz ◽  
Hanna Romanowicz-Makowska ◽  
Andrzej Kulig
Keyword(s):  
Colorectal Cancer ◽  
Plasminogen Activator ◽  
Pcr Amplification ◽  
Plasminogen Activator Inhibitor ◽  
Cancer Tissue ◽  
Plasminogen Activator Inhibitor 1 ◽  
Gene Encoding ◽  
Gene Variability ◽  
Activator Inhibitor ◽  
Pai 1

Plasminogen activator inhibitor 1 (PAI-1) content in colorectal cancer tissue extracts may be of strong prognostic value: high levels of PAI-1 in tumours predict poor prognosis. The gene encoding PAI-1 is highly polymorphic and PAI-1 gene variability could contribute to the level of PAI-1 biosynthesis. In the present work the distribution of genotypes and frequency of alleles of the 1334G/A polymorphism in 92 subjects with colorectal cancer in samples of cancer tissue and distant mucosa samples as well as in blood were investigated. Blood samples age matched healthy individuals (n = 110) served as control. The 1334G/A polymorphism was determined by PCR amplification using allele specific primers. No differences in the genotype distributions and allele frequencies between blood, distant mucosa samples and cancer tissue were detected. However, the distribution of the genotypes of the 1334G/A polymorphism in patients differed significantly (P

The Prognostic Value of Vascular Endothelial Growth Factor, Urokinase Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Node-Negative Breast Cancer

2004 ◽  
Vol 19 (4) ◽  
pp. 282-288 ◽  
Author(s):  
S. Meo ◽  
R. Dittadi ◽  
L. Peloso ◽  
M. Gion
Keyword(s):  
Breast Cancer ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Vascular Endothelial ◽  
Plasminogen Activator Inhibitor 1 ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Endothelial Growth Factor ◽  
The Relationship ◽  
Pai 1

The vascular endothelial growth factor (VEGF) and the plasminogen activator system play an essential role in solid tumor angiogenesis and in tumor invasion and metastasis. In the present study we investigated the relationship between patient outcome and levels of VEGF, urokinase plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) in tumor cytosols of 196 node-negative primary invasive breast cancer patients who did not receive any adjuvant therapy. The median follow-up was 65 months. VEGF, uPA and PAI-1 were measured by commercially available enzyme-linked immunosorbent assays. Cox's univariate analysis showed that pT (p=0.0007), uPA (p=0.0156) and PAI-1 (p=0.0015) had a significant impact on relapse-free survival, whereas VEGF did not have any prognostic value (p=0.18). Bivariate analysis showed significant interactions between uPA and PAI-1 (p=0.0035) and between VEGF and PAI-1 (p=0.006). Our study confirms that uPA and PAI-1 cytosol levels can be considered as prognostic factors for relapse-free survival in node-negative breast cancer. Moreover, the interaction between VEGF and PAI-1 warrants further investigation into the relationship between the biomarkers of angiogenesis and those of the protease cascade.

scholarly journals Obesity and Breast Cancer: The Roles of Peroxisome Proliferator-Activated Receptor-γand Plasminogen Activator Inhibitor-1

PPAR Research ◽  
2009 ◽  
Vol 2009 ◽  
pp. 1-13 ◽  
Author(s):  
Jennifer C. Carter ◽  
Frank C. Church
Keyword(s):  
Breast Cancer ◽  
Plasminogen Activator ◽  
High Fat Diet ◽  
Plasminogen Activator Inhibitor ◽  
Peroxisome Proliferator ◽  
High Fat ◽  
Plasminogen Activator Inhibitor 1 ◽  
Peroxisome Proliferator Activated Receptor ◽  
Activator Inhibitor ◽  
Pai 1

Breast cancer is the most prominent cancer among females in the United States. There are a number of risk factors associated with development of breast cancer, including consumption of a high-fat diet and obesity. Plasminogen activator inhibitor-1 (PAI-1) is a cytokine upregulated in obesity whose expression is correlated with a poor prognosis in breast cancer. As a key mediator of adipogenesis and regulator of adipokine production, peroxisome proliferator-activated receptor-γ(PPAR-γ) is involved in PAI-1 expression from adipose tissue. We summarize the current knowledge linking PPAR-γand PAI-1 expression to high-fat diet and obesity in the risk of breast cancer.

Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer

2009 ◽  
Vol 124 (4) ◽  
pp. 403-408 ◽  
Author(s):  
Raffaele Palmirotta ◽  
Patrizia Ferroni ◽  
Annalisa Savonarola ◽  
Francesca Martini ◽  
Filippo Ciatti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Plasminogen Activator ◽  
Prognostic Value ◽  
Plasminogen Activator Inhibitor ◽  
Plasminogen Activator Inhibitor 1 ◽  
Activator Inhibitor ◽  
Pai 1
Sign in / Sign up

Export Citation Format

Share Document